EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bridging HFpEF Across the Care Continuum: From Screening to Phenotyping and Targeted Management

Vebiona Kartini Prima Putri, Siti Elkana Nauli, Raja Ezman Faridz Raja Shariff

Indonesian Journal of Cardiology · 11.06.2026 · 47 (2) · 168-188

DOI: 10.30701/ijc.2190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indonesian Journal of Cardiology, online erschienen am 11.06.2026. Verfasst von Vebiona Kartini Prima Putri und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart Failure with preserved Ejection Fraction (HFpEF) has become an important form of Heart Failure (HF), characterized by marked heterogeneity in pathophysiology, clinical presentation, and treatment response. It is an increasingly prevalent form of HF driven by aging populations and comorbidities such as hypertension, diabetes, obesity, and Chronic Kidney Disease (CKD). HFpEF is also associated with high morbidity, frequent hospitalizations, and diagnostic challenges, particularly in resource-limited settings. This manuscript provides a clinically focused overview of HFpEF, integrating current concepts in pathophysiology, diagnosis, phenotyping, and management. Its pathophysiology is multifactorial, involving systemic inflammation, endothelial dysfunction, myocardial stiffness, and contributions from comorbid conditions. Emerging evidence highlights the roles of adiposity and inflammatory pathways, reinforcing the view of HFpEF as a multisystem disorder rather than purely a cardiac condition. The condition is also markedly heterogeneous, with several phenotypes identified, including cardiometabolic, obesity-related, cardiorenal, chronotropic incompetence, and Atrial Fibrillation (AF)–associated HFpEF. These phenotypes influence disease progression and therapeutic response. Additionally, numerous clinical mimics, such as pulmonary disease, valvular heart disease, and infiltrative cardiomyopathies, complicate diagnosis. Diagnosis requires a structured, probability-based approach combining clinical assessment, biomarkers, echocardiography, and, when necessary, stress testing or invasive hemodynamics. However, limited access to advanced diagnostics necessitates pragmatic, tiered approaches, especially in low-resource settings. Management focuses on three pillars: optimization of comorbidities, guideline-directed medical therapy, and phenotype-specific treatment strategies. While no therapy conclusively reduces mortality, recent advances have improved symptom control and hospitalizations. Overall, HFpEF demands a holistic, individualized approach integrating pathophysiology, clinical phenotyping, and healthcare system constraints to improve patient outcomes.

Zitieren

APA

Putri, V. K. P., Nauli, S. E., & Shariff, R. E. F. R. (2026). Bridging HFpEF Across the Care Continuum: From Screening to Phenotyping and Targeted Management. Indonesian Journal of Cardiology, 47(2), 168-188. https://doi.org/10.30701/ijc.2190

Vancouver

Putri VKP, Nauli SE, Shariff REFR. Bridging HFpEF Across the Care Continuum: From Screening to Phenotyping and Targeted Management. Indonesian Journal of Cardiology. 2026;47(2):168-188. doi:10.30701/ijc.2190

BibTeX
@article{Putri2026,
  author = {Putri, Vebiona Kartini Prima and Nauli, Siti Elkana and Shariff, Raja Ezman Faridz Raja},
  title = {Bridging HFpEF Across the Care Continuum: From Screening to Phenotyping and Targeted Management},
  journal = {Indonesian Journal of Cardiology},
  year = {2026},
  volume = {47},
  number = {2},
  pages = {168--188},
  doi = {10.30701/ijc.2190}
}
Kostenlos starten →